Serologic Screening for Genital Herpes
An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

Cynthia Feltner, MD, MPH; Catherine Grodensky, MPH; Charles Ebel, BA; Jennifer C. Middleton, PhD; Russell P. Harris, MD, MPH; Mahima Ashok, PhD, MS; Daniel E. Jonas, MD, MPH

IMPORTANCE Genital herpes simplex virus (HSV) infection is a prevalent sexually transmitted infection. Vertical transmission of HSV can lead to fetal morbidity and mortality.

OBJECTIVE To assess the evidence on serologic screening and preventive interventions for genital HSV infection in asymptomatic adults and adolescents to support the US Preventive Services Task Force for an updated recommendation statement.

DATA SOURCES MEDLINE, Cochrane Library, EMBASE, and trial registries through March 31, 2016. Surveillance for new evidence in targeted publications was conducted through October 31, 2016.

STUDY SELECTION English-language randomized clinical trials (RCTs) comparing screening with no screening in persons without past or current symptoms of genital herpes; studies evaluating accuracy and harms of serologic screening tests for HSV-2; RCTs assessing preventive interventions in asymptomatic persons seropositive for HSV-2.

DATA EXTRACTION AND SYNTHESIS Dual review of abstracts, full-text articles, and study quality; pooled sensitivities and specificities of screening tests using a hierarchical summary receiver operating characteristic curve analysis when at least 3 similar studies were available.

MAIN OUTCOMES AND MEASURES Accuracy of screening tests, benefits of screening, harms of screening, reduction in genital herpes outbreaks.

RESULTS A total of 17 studies (n = 9736 participants; range, 24-3290) in 19 publications were included. No RCTs compared screening with no screening. Most studies of the accuracy of screening tests were from populations with high HSV-2 prevalence (greater than 40% based on Western blot). Pooled estimates of sensitivity and specificity of the most commonly used test at the manufacturer’s cutpoint were 99% (95% CI, 97%-100%) and 81% (95% CI, 68%-90%), respectively (10 studies; n = 6537). At higher cutpoints, pooled estimates were 95% (95% CI, 91%-97%) and 89% (95% CI, 82%-93%), respectively (7 studies; n = 5516). Use of this test at the manufacturer’s cutpoint in a population of 100 000 with a prevalence of HSV-2 of 16% (the seroprevalence in US adults with unknown symptom status) would result in 15 840 true-positive results and 15 960 false-positive results (positive predictive value, 50%). Serologic screening for genital herpes was associated with psychosocial harms, including distress and anxiety related to positive test results. Four RCTs compared preventive medications with placebo, 2 in nonpregnant asymptomatic adults who were HSV-2 seropositive and 2 in HSV-2-serodiscordant couples. Results in both populations were heterogeneous and inconsistent.

CONCLUSIONS AND RELEVANCE Serologic screening for genital herpes is associated with a high rate of false-positive test results and potential psychosocial harms. Evidence from RCTs does not establish whether preventive antiviral medication for asymptomatic HSV-2 infection has benefit.
Genital herpes is a sexually transmitted infection (STI) caused by herpes simplex virus (HSV) type 1 or type 2. Many patients experience signs and symptoms during primary infection and recurrences, but some may have mild or no symptoms. Episodic subclinical viral shedding leads to the potential for transmission in the absence of symptoms. HSV-2 accounts for most prevalent genital herpes cases and is more likely to cause frequent symptomatic recurrences than HSV-1 (which is most commonly acquired in childhood and associated with orofacial infection). Genital HSV infection during pregnancy poses a risk of neonatal transmission during delivery, particularly among women who acquire HSV near the time of delivery.

The true prevalence of asymptomatic HSV-2 infection is unknown; prevalence estimates rely on serologic test results and are not confirmed with Western blot. The estimated seroprevalence of HSV-2 in the United States was 16% in 2005-2010; only 14% of seropositive persons reported having been diagnosed with genital herpes. It is unclear what proportion of HSV-2-seropositive participants with no prior diagnosis of genital herpes had true asymptomatic (or unrecognized) infection vs a false-positive test result.

In theory, screening to identify unrecognized HSV-2 infection followed by counseling, antiviral treatment (episodic or suppressive), or both could prevent transmission and reduce symptoms and shedding. Several US Food and Drug Administration (FDA)-approved type-specific HSV serologic tests are available. Since HSV-2 rarely causes infection outside the anogenital region, HSV-2 antibodies can be interpreted as an indicator of genital infection.

In 2005, the US Preventive Services Task Force (USPSTF) recommended against routine serologic screening for HSV in asymptomatic adolescents, adults, and pregnant women (grade D recommendation). To inform an updated recommendation, we reviewed the evidence on benefits and harms of serologic screening for HSV-2, screening test accuracy, and benefits and harms of antiviral treatment in populations relevant to US primary care.

Methods
Scope of Review
Detailed methods are available in the full evidence report at https://www.uspreventiveservicestaskforce.org/Page/Document /final-evidence-review/genital-herpes-screening1. The full evidence report also provides additional information about the proposed methods for key question (KQ) 7 (focused on the association between subclinical genital HSV-2 viral shedding and health outcomes), additional background and contextual information about genital herpes in the United States, and a list of studies that were excluded during the full-text review phase of the literature search.

Figure 1 shows the analytic framework and KQs that guided the review.

Data Sources and Searches
PubMed/MEDLINE, the Cochrane Library, and EMBASE were searched for English-language articles published through March 31, 2016. Search strategies are listed in eMethods in the Supplement. We searched for unpublished literature in ClinicalTrials.gov and the World Health Organization’s International Clinical Trials Registry Platform. To supplement electronic searches, reference lists of pertinent articles and suggested citations from reviewers were reviewed. We conducted ongoing surveillance after March 2016 through article alerts and targeted searches of high-impact journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and related USPSTF recommendation. The last surveillance was conducted on October 31, 2016.

Study Selection
Two investigators independently reviewed titles, abstracts, and full-text articles to determine eligibility using prespecified criteria (eTable 1 in the Supplement). Disagreements were resolved by discussion. English-language studies of immunocompetent adults or adolescents, including pregnant women, were included. Only studies rated as good or fair quality were included. For all KQs, studies of persons without symptoms or a clinical history of genital herpes were eligible, as were studies of asymptomatic partners of persons with known genital herpes (ie, discordant couples). For the overarching question on direct evidence that screening improves health outcomes (KQ1), only randomized clinical trials (RCTs) comparing groups that were screened with groups that were not screened were included.

For KQ2 (accuracy of serologic tests), we included studies of FDA-approved serologic tests for HSV-2 that reported accuracy compared with the Western blot, which has been used as a reference standard in studies assessing commercially available serologic tests in the United States. Eligible populations could be symptomatic, asymptomatic, or a combination of both.

For KQ3 (harms of screening), we included trials, systematic reviews, and observational studies assessing the harms of screening in asymptomatic populations with no prior diagnosis of genital herpes, with or without a comparison group.

For studies assessing benefits or harms of preventive medications in asymptomatic populations (KQ4 through KQ6), RCTs comparing FDA-approved oral antiviral medications for the suppression of recurrent genital herpes (acyclovir, famciclovir, or valacyclovir) with placebo were eligible. RCTs of behavioral counseling interventions (eg, education or counseling; partner notification; barrier protection; or combinations of these components) were also eligible. For studies assessing the harms of antiviral medications in pregnant women (KQ5b), multi-institution antiviral medication pregnancy exposure registries were eligible. Eligible outcomes included reduced rates of symptomatic episodes and transmission (including measures of HSV-2 seroconversion). For KQ5b effectiveness of interventions in pregnant women, eligible outcomes also included rates of neonatal HSV infection and reduced rates of symptomatic genital herpes at delivery. For KQ4 (effects of antiviral medication on subclinical HSV-2 shedding), we included any outcome measure of subclinical HSV-2 shedding (eg, percentage of days with any shedding detected).

Data Extraction and Quality Assessment
For each included study, one investigator extracted information about design, population, tests or treatments used, and outcomes, and a second investigator reviewed for completeness and accuracy. Two independent investigators assessed the quality of each study as good, fair, or poor, using predefined criteria developed by
the USPSTF and adapted for this topic (eTables 2-3 in the Supplement). Individual study quality ratings are provided in the Supplement (eTables 4-7).

Data Synthesis and Analysis
Findings for each question were summarized in tabular and narrative form. To determine whether meta-analyses were appropriate, the clinical and methodological heterogeneity of the studies was assessed following established guidance. To do this, we qualitatively assessed the similarities and differences in populations, tests, treatments, comparators, outcomes, and designs. For KQ2 (the only KQ with sufficient numbers of similar studies for quantitative syntheses), pooled sensitivities and specificities for each type of serologic test were calculated using a hierarchical summary receiver operating characteristic (HSROC) curve analysis when at least 3 similar studies were available. Separate models
were developed for each type of serologic test, and separate analyses were conducted for HerpeSelect using the manufacturer-recommended cutpoint for test positivity and for higher cutpoints reported in the literature to determine whether accuracy is improved with using higher cutpoints. The metandi program in Stata version 14.12 was used to conduct all quantitative analyses.

Results

Seventeen included studies with a total of 9736 participants (range, 24-3290) and reported in 19 publications were identified (Figure 2).13-29

Benefits of Screening

Key Question 1a. Does serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in asymptomatic nonpregnant adults and adolescents reduce future symptomatic episodes and transmission of genital herpes?

Key Question 1b. Does serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in pregnant women reduce neonatal HSV infection and symptomatic episodes of genital herpes at delivery?

No eligible studies were identified.

Accuracy of HSV-2 Serologic Screening Tests

Key Question 2. What is the accuracy of serologic screening for HSV-2 in asymptomatic adults, adolescents, and pregnant women?

We included 11 good- or fair-quality studies (n = 7129; range, 61-3290) assessing the accuracy of 1 or more type-specific HSV-2 serologic tests compared with Western blot.13-23 All 11 studies enrolled adults and none enrolled pregnant women. Most studies (8) enrolled a population with HSV-2 prevalence greater than 40% based on Western blot (range, 41%-70%). Two included studies described whether participants had current or prior symptoms consistent with genital herpes17,30; 1 study enrolled US college students with no current or previous symptoms consistent with genital herpes,30 and the other enrolled men seeking care at US STI clinics (17% were later diagnosed with genital herpes).17 In the 9 other studies, the proportion of participants who had current or past symptoms of genital herpes was not described. Most studies enrolled participants from 1 or more African countries; 3 were set in the United States,13,17,18 and 1 enrolled participants from multiple countries (Argentina, Costa Rica, Korea, Mexico, Nigeria, Thailand, and Vietnam).14

All 11 studies compared the Focus HerpeSelect HSV-2 enzyme-linked immunosorbent assay with Western blot and used a test cutpoint value of 1.1 to define a positive test result (current manufacturer’s cutpoint). Seven studies also assessed higher test cutpoints to boost specificity (ranging from 2.1 to 3.5).14,15,19,21-23 Four studies also assessed accuracy of the biokit HSV-2 Rapid Test.18,20-22 Further study characteristics are shown in Table 1.

Ten studies (n = 6537 participants analyzed; range, 89-3290) provided sufficient data to estimate sensitivity and specificity of HerpeSelect using a cutpoint value of 1.1;13-16,18-23; individual study
<table>
<thead>
<tr>
<th>Source</th>
<th>Analytic Sample Size</th>
<th>Eligible Serologic Tests</th>
<th>Population</th>
<th>Recruitment Setting; Country</th>
<th>Age, Mean (SD), y</th>
<th>Sex and Race, %</th>
<th>STI Comorbidity, %</th>
<th>HSV-1 Positive, %</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley-Morrow et al,14 2004</td>
<td>675</td>
<td>HerpeSelect</td>
<td>Women aged ≥15 y participating in an HSV seroprevalence study</td>
<td>Study participants; multinationala</td>
<td>NR</td>
<td>Women: 100</td>
<td>Nonwhite: NR</td>
<td>93-99 (by WB)</td>
<td>Fair</td>
</tr>
<tr>
<td>Delany-Moretlwe et al,23 2010</td>
<td>98</td>
<td>HerpeSelect</td>
<td>Adult women with unknown HSV-2 serostatus</td>
<td>Family planning clinics; South Africa</td>
<td>26 (range, 18-46)</td>
<td>Women: 100</td>
<td>Nonwhite: NR</td>
<td>52 (HIV-1)</td>
<td>NR</td>
</tr>
<tr>
<td>Golden et al,17 2005</td>
<td>61</td>
<td>HerpeSelect</td>
<td>Men who had been tested for HSV at an STI clinic between 2001-2002</td>
<td>2 county STI clinics; United States</td>
<td>Median, 35 (range, 18-73)</td>
<td>Women: 0</td>
<td>Nonwhite: 23</td>
<td>1</td>
<td>56 (by WB)</td>
</tr>
<tr>
<td>Hogrefe et al,19 2002</td>
<td>776</td>
<td>HerpeSelect</td>
<td>Adults, varied by location; Kenya: women enrolled in a vitamin A study; Uganda: (1) serologic samples from participants in an HIV seroprevalence study, (2) samples from HIV-negative women South Africa and Namibia: samples initially collected for HIV screenings from healthy, primarily middle-income individuals</td>
<td>Varied by location—primarily study participants; multiple African countriesb</td>
<td>NR</td>
<td>Women: NR</td>
<td>Nonwhite: NR</td>
<td>89-100 (by WB)</td>
<td>Fair</td>
</tr>
<tr>
<td>Lingappa et al,21 2010</td>
<td>467</td>
<td>HerpeSelect; biokit HSV-2</td>
<td>Adults participating in a study of genital herpes seroprevalence and incidence</td>
<td>Study participants; Uganda</td>
<td>NR</td>
<td>Women: NR</td>
<td>Nonwhite: NR</td>
<td>12 (HIV-1)</td>
<td>NR</td>
</tr>
<tr>
<td>Mark et al,13 2007; Mark et al,30 2008</td>
<td>89</td>
<td>HerpeSelect</td>
<td>Urban university students with no history of genital herpes or genital sores who reported being sexually active within the past 6 mo</td>
<td>Recruited by flyers, announcements, and online/newspaper advertisements at 1 university; United States</td>
<td>25 (4.4)</td>
<td>Women: 64</td>
<td>Nonwhite: 31</td>
<td>9 (by HerpeSelect); 3 (by WB)</td>
<td>Good</td>
</tr>
<tr>
<td>Morrow et al,18 2005</td>
<td>782</td>
<td>HerpeSelect; biokit HSV-2</td>
<td>Two populations enrolled: (1) adult MSM screened for enrollment in a clinical trial assessing acyclovir to reduce HIV transmission and (2) consecutive serologic samples submitted for HSV WB testing</td>
<td>Study participants and serologic samples sent to the University of Washington Virology Laboratory during a 4-wk period; United States</td>
<td>NR</td>
<td>Women: 0</td>
<td>Nonwhite: NR</td>
<td>64 (by WB)</td>
<td>Fair</td>
</tr>
<tr>
<td>Ng'ayo et al,22 2010</td>
<td>233</td>
<td>HerpeSelect; biokit HSV-2</td>
<td>Adult men who worked in the fishing industry who reported being sexually active in the previous 2 wk</td>
<td>Community (beaches along Lake Victoria); Kenya</td>
<td>NR (≥18 y eligible)</td>
<td>Women: 0</td>
<td>Nonwhite: NR</td>
<td>NR</td>
<td>Fair</td>
</tr>
</tbody>
</table>
results are shown in eTable 8 in the Supplement. Pooled estimates of sensitivity and specificity were 99% (95% CI, 97%-100%) and 81% (95% CI, 68%-90%), respectively (Table 2). eFigure 1 in the Supplement shows the HSROC with 95% confidence ellipse using pairs of sensitivity and specificity. Estimates for specificity were highly variable, ranging from 41% to 97.5%. Studies handled equivocal (or indeterminate) test results in various ways, which may contribute to heterogeneity in estimates of test accuracy (eTable 8 in the Supplement). Five studies (n = 1840; range, 89-776) reported a positive predictive value using the manufacturer's cutpoint; estimates ranged from 37.5 to 86.0. Four studies (n = 1512 participants analyzed; range, 98-782) reported no history of genital herpes.

Abbreviations: HIV, human immunodeficiency virus; HSV, herpes simplex virus; MSM, men who have sex with men; NR, not reported; STI, sexually transmitted infection; WB, Western blot.

*Randomized trial of acyclovir (for HSV-2 suppressive therapy) to reduce HIV-1 transmission.
†Kenya, Rwanda, Tanzania, Uganda, Botswana, South Africa, Zambia.
‡Kenya, Zambia, Benin, Cameroon.

Harms of HSV-2 Serologic Screening in Asymptomatic Populations

Key Question 3a. What are the harms of serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in asymptomatic nonpregnant adolescents and adults?

Key Question 3b. What are the harms of serologic screening for HSV-2 or combined testing for HSV-1 and HSV-2 in asymptomatic pregnant women?

Characteristics and outcomes of the 2 included fair-quality studies are shown in eTable 10 in the Supplement. Both studies were set in the United States and assessed the effect of a positive HSV-2 serologic test result on psychosocial outcomes among people who reported no history of genital herpes.

The first study (n = 24) was a qualitative assessment of the psychosocial effects of receiving an HSV-2 diagnosis based on serologic testing. Investigators recruited 24 adult participants reporting no history of genital herpes who tested HSV-2 seropositive by Western blot. Participants were recruited from clinical settings (STI, maternal and infant care, family medicine, and research clinics) and completed in-depth interviews on their experience of

---

**Table 1. Characteristics of Included Studies Assessing the Accuracy of Serologic Screening Tests for HSV-2 (Key Question 2) (continued)**

| Source | Analytic Sample Size | Eligible Serologic Tests | Population | Recruitment Setting, Country | Age, Mean (SD), y | Sex and Race, % | STI Comorbidity, % | HSV-1 Positive, % | Study Quality |
|---|---|---|---|---|---|---|---|---|---|---|
| Smith et al,16 2009 | 99 | HerpeSelect | Adult HIV-negative men participating in a trial to determine the effectiveness of circumcision in reducing HIV incidence | Study participants (recruited from STI clinics, workplaces, and community organizations); Kenya | NR | Women: 0 Nonwhite: NR | NR | NR | Fair |
| Van Dyck et al,15 2004 | 330 | HerpeSelect; biokit HSV-2 | Adults who were enrolled in a study determining the spread of HIV | Study participants; multiple African countries* | NR (15-49 y eligible) | Women: NR Nonwhite: NR | NR | NR | Fair |

**Table 2. Accuracy of Serologic Screening Tests for HSV-2 Compared With Western Blot (Key Question 2)**

<table>
<thead>
<tr>
<th>HerpeSelect</th>
<th>1.1 Cutpoint</th>
<th>2.2-3.5 Cutpoint</th>
<th>biokit HSV-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies, No.</td>
<td>10</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Participants, No.</td>
<td>6537</td>
<td>5516</td>
<td>1512</td>
</tr>
<tr>
<td>Sensitivity (95% CI), %</td>
<td>99 (97-100)</td>
<td>95 (91-97)</td>
<td>84 (73-91)</td>
</tr>
<tr>
<td>Specificity (95% CI), %</td>
<td>81 (68-90)</td>
<td>89 (82-93)</td>
<td>95 (93-97)</td>
</tr>
<tr>
<td>Likelihood ratio (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>5 (3-10)</td>
<td>8 (5-13)</td>
<td>17 (11-29)</td>
</tr>
<tr>
<td>Negative</td>
<td>0.01 (0.003-0.04)</td>
<td>0.06 (0.036-0.099)</td>
<td>0.16 (0.02-0.30)</td>
</tr>
</tbody>
</table>

**Abbreviation:** HSV-2, herpes simplex virus type 2.
HSV-2 diagnosis. The qualitative analysis identified 3 categories of themes: (1) short-term, emotional responses that included surprise, denial, confusion, distress, sadness, disappointment, and relief to know; (2) short-term, psychological responses that included fear of telling sex partners, anger at the source partner, guilt about acquiring or transmitting, and concern about transmitting to a child; and (3) perceived ongoing responses that included fear of telling future partners, concern about transmitting to a sex partner, feeling sexually undesirable, feeling socially stigmatized, feeling like “damaged goods,” sex avoidance because of social responsibility, fear of transmitting to a newborn child, and relationship concerns relating to the diagnosis. The authors concluded that participants exhibited strong emotional and psychological responses to their serologic diagnoses of HSV-2, while observing that some of these responses were time limited.

The second study (n = 33) enrolled individuals aged 14 to 30 years from an urban university setting and various clinical settings, including STI, primary care, and adolescent clinics. Of the 1190 enrolled, 820 (68%) had serologic testing (type of test not described) and 149 (18%) were HSV-2–positive. Of those participants who screened positive for HSV-2, 93 (62%) returned for their initial test results and 33 returned for the 3-month follow-up. At 3 months, participants completed the herpes Health-Related Quality of Life Questionnaire (HRQOLQ). Participants responded to each item using a 4-point scale that ranged from “very” to “not at all.” For individual-item analysis, answers of “very” or “quite” were considered indicative of endorsing the experience. A number of individual HRQOLQ items were endorsed frequently as “very” or “quite,” including the following: “It is difficult to forget that I have herpes” (63%); “I worry about giving herpes to someone” (56%); and “I worry about people finding out I have herpes” (48%). Other items from the HRQOLQ endorsed less frequently are shown in eTable 10 in the Supplement.

Effectiveness of Preventive Interventions for Asymptomatic HSV-2-Seropositive Populations

Key Question 4. How effective are oral antiviral medications in reducing genital HSV-2 viral shedding in asymptomatic adolescents, adults, and pregnant women?

We included 2 fair-quality RCTs (n = 129; range, 63-66) that compared daily preventive antiviral medication with placebo over 6 to 8 weeks (Table 3). One study did not describe how symptoms of genital herpes were ascertained; the other reported that participants who underwent HSV serologic testing as part of their clinical care but reported no current or prior symptoms consistent with genital herpes. One RCT (n = 63) assessed valacyclovir (1 g daily) and the other (n = 66) assessed famciclovir (250 mg twice daily). In both studies, participants were instructed to return to the clinic any time they suspected an outbreak. At 2 months, fewer participants in the valacyclovir group reported symptoms of genital herpes than in the placebo group (12% vs 23%, respectively). The authors report that the treatment effect was significant (P = .033, controlling for the crossover effect); however, the arithmetic mean of the difference between groups was not significant (11% [95% CI, −0.6% to 22%]). In the RCT assessing famciclovir (n = 66), the incidence of genital herpes symptoms was similar in the famciclovir and placebo groups at 6 weeks (17.5% and 17.2%, respectively; P value not reported).

Quality limitations across both trials included attrition (23%-29% of participants), unclear handling of missing data, and risk of measurement bias. Symptoms were ascertained by self-report (not using a validated questionnaire) over a relatively short duration (6-8 weeks). One study enrolled participants who had HSV serologic testing as part of their clinical care; results may not be applicable to those who screen positive but are not seeking testing for HSV infection.

Two RCTs compared the benefit of daily suppressive antiviral medication with placebo for preventing genital herpes transmission between HSV-2–serodiscordant heterosexual couples; one measured outcomes at 8 months and the other at 12 to 24 months. One RCT enrolled immunocompetent couples, while the other was a substudy of HIV-1–serodiscordant couples in which the HIV-1-negative partner was also susceptible to HSV-2. One RCT (n = 1484 couples) assessed valacyclovir (500 mg daily), and the other (n = 937 couples) assessed acyclovir (400 mg daily); in
<table>
<thead>
<tr>
<th>Source</th>
<th>Population</th>
<th>Recruitment Setting, Country</th>
<th>Group Information</th>
<th>Treatment Duration, wk</th>
<th>HSV-2 Test</th>
<th>Age, Mean (SD), y</th>
<th>Sex and Race, %</th>
<th>HSV-1 Positive, %</th>
<th>Viral Shedding Outcome Measure, Results</th>
<th>Symptomatic Episodes Outcome Measure Results</th>
<th>HSV-2 Transmission Outcome Measure Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leone et al.27</td>
<td>Adults ≥18 y seropositive for HSV-2 with no history of symptomatic genital herpes</td>
<td>7 centers (not otherwise specified); United States</td>
<td>Total (66) Group 1: famciclovir (250 mg twice daily) first (NR) Group 2: placebo first (NR)</td>
<td>6</td>
<td>Western blot</td>
<td>Median, 38 (range, 18-68)</td>
<td>Women: 64 Nonwhite: 35</td>
<td>55</td>
<td>Participants with any shedding, No. (%). Group 1: 27 (42.9) Group 2: 29 (50.0) P = NR Days with any subclinical viral shedding, mean (%). Group 1: 14/2777 (5.0) Group 2: 122/2141 (5.7) P &lt; .52 Reduction in subclinical shedding risk, group 1 vs group 2: RR, 0.80 (95% CI, 0.41-1.56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sperling et al.28</td>
<td>Adults ≥18 y seropositive for HSV-2 with no active lesions or symptoms consistent with genital herpes</td>
<td>13 clinical settings (STI clinics, primary care clinics, and gynecology practices); United States</td>
<td>Total (63) Group 1: valacyclovir (1 g daily) first (36) Group 2: placebo first (37)</td>
<td>8</td>
<td>HerpeSelectc</td>
<td>37 (NR)</td>
<td>Women: 75 Nonwhite: 35</td>
<td>56-57</td>
<td>Participants with no shedding, No. (%). Group 1: 47 (84) Group 2: 30 (54) P &lt; .001 Percentage of days with any subclinical viral shedding, mean (SD). Group 1: 1.5 (5.3) Group 2: 1.5 (5.1) P &lt; .001c</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Table 3. Characteristics and Results of Randomized Clinical Trials Assessing Antiviral Medications in Adults (Key Questions 4 and 5)\(^a\) (continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Population</th>
<th>Recruitment Setting, Country</th>
<th>Group Information</th>
<th>Treatment Duration, wk</th>
<th>HSV-2 Test</th>
<th>Age, Mean (SD), y</th>
<th>Sex and Race, %</th>
<th>HSV-1 Positive, %</th>
<th>Viral Shedding</th>
<th>Symptomatic Episodes</th>
<th>HSV-2 Transmission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corey et al,(^28) 2004</td>
<td>Adult (≥18 y) HSV-2 serodiscordant heterosexual couples</td>
<td>96 study sites (not otherwise specified); United States, Canada, Europe, Latin America, Australia</td>
<td>Total (1,484 couples) Group 1: valacyclovir (500 mg once daily) (743 couples) Group 2: placebo (741 couples)</td>
<td>32 Western blot</td>
<td>Median, 34–34 (range, 18–76)</td>
<td>Women: 33 Nonwhite: 10–11</td>
<td>70</td>
<td>NR</td>
<td>NR</td>
<td>HSV-2 seroconversions, No. (%), Group 1: 14 (1.9) Group 2: 27 (3.6) HR, 0.52 (95% CI, 0.27–0.99) P = .04 Incidence of symptomatic genital herpes, No. (%), Group 1: 4 (0.5) Group 2: 16 (2.2) HR, 0.25 (95% CI, 0.08–0.75) P = .008</td>
<td></td>
</tr>
<tr>
<td>Kim et al,(^29) 2008</td>
<td>Adult (≥18 y) HSV-2 serodiscordant heterosexual couples</td>
<td>96 study sites (not otherwise specified); United States, Canada, Europe, Latin America, Australia</td>
<td>Total (1,484 couples) Group 1: valacyclovir (500 mg once daily) (743 couples) Group 2: placebo (741 couples)</td>
<td>32 Western blot</td>
<td>Median, 34–34 (range, 18–76)</td>
<td>Women: 33 Nonwhite: 10–11</td>
<td>70</td>
<td>NR</td>
<td>NR</td>
<td>HSV-2 seroconversions, No. (%), Group 1: 14 (1.9) Group 2: 27 (3.6) HR, 0.52 (95% CI, 0.27–0.99) P = .04 Incidence of symptomatic genital herpes, No. (%), Group 1: 4 (0.5) Group 2: 16 (2.2) HR, 0.25 (95% CI, 0.08–0.75) P = .008</td>
<td></td>
</tr>
<tr>
<td>Mujugira et al,(^32) 2013</td>
<td>HSV-2 serodiscordant heterosexual couples enrolled into the Partners in Prevention HSV/HIV Transmission study(^b); couples were also serodiscordant for HIV (HSV-2–infected partners were also infected with HIV)</td>
<td>14 study sites (not specified); Kenya, Rwanda, Tanzania, Uganda, Botswana, South Africa, Zambia</td>
<td>Total (937 couples) Group 1: acyclovir (400 mg twice daily) (458 couples) Group 2: placebo (453 couples)</td>
<td>78 HerpeSelect(^f)</td>
<td>Median, 31 (IQR, 27–38)</td>
<td>Women: 12 Nonwhite: NR</td>
<td>≥99</td>
<td>NR</td>
<td>NR</td>
<td>HSV-2 seroconversions, No., Group 1: 40 Group 2: 28 HSV-2 incidence, HR, 1.35 (95% CI, 0.83–2.20) P = .220</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: HIV, human immunodeficiency virus; HR, hazard ratio; HSV, herpes simplex virus; IQR, interquartile range; NR, not reported; RR, relative risk; STI, sexually transmitted infection.

\(^a\) Quality of evidence was fair for all studies in this table.

\(^b\) Participants had undergone specific HSV serologic testing either as part of their clinical care or in response to local advertisements offering free HSV serologic testing.

\(^c\) Samples with an index value of 11 to 3.5 were confirmed with HSV-2 IgG inhibition assay to eliminate false-positive test results.

\(^d\) Persons with at least 1 swab during each crossover period.

\(^e\) Nonparametric crossover analysis methods in the intention-to-treat crossover population (all participants who had at least 1 dose of medication and 1 polymerase chain reaction result in each treatment period).

\(^f\) Samples with an index value of 3.5 or greater were considered positive to improve test specificity and confirmed by Western blot.
both studies, antiviral medication was provided to the infected partner. Both studies were conducted in multiple countries; one enrolled from 96 study sites in the United States, Canada, Europe, Latin America, and Australia, and one was conducted in 7 sub-Saharan African countries.

The 2 trials found conflicting results (Table 3). In the RCT assessing valacyclovir, fewer HSV-2–susceptible partners in the valacyclovir group had symptomatic HSV-2 infection than partners randomized to placebo over 8 months (0.5% vs 2.2%, respectively; hazard ratio, 0.25 [95% CI, 0.08-0.75]); similarly, fewer HSV-2–susceptible partners in the valacyclovir group seroconverted to HSV-2 than those in the placebo group (1.9% vs 3.6%, respectively; \( P = .04 \); hazard ratio, 0.52 [95% CI, 0.27-0.99]). In contrast, the RCT assessing acyclovir use among HIV-1-serodiscordant couples did not find a reduction in transmission. At follow-up (median, 18 months), the number of susceptible partners with seroconversions was not statistically different between the acyclovir group (40) and placebo group (28), which indicated seroincidence of 5.9 and 4.3 cases per 100 person-years, respectively (hazard ratio, 1.35 [95% CI, 0.83-2.20]; \( P = .22 \)).

Key limitations across both trials included high attrition; 22% of couples withdrew from one trial, and the overall attrition was 66% in the other trial.

### Harms of Preventive Interventions for Asymptomatic HSV-2–Seropositive Populations

**Key Question 6a.** What are the harms of preventive medications and behavioral counseling interventions for reducing future symptomatic episodes and transmission of genital herpes in asymptomatic nonpregnant adults and adolescents?

**Key Question 6b.** What are the harms of preventive medications and behavioral counseling interventions for reducing neonatal HSV infection and symptomatic episodes of genital herpes at delivery in asymptomatic pregnant women?

One RCT (n = 63) included in KQ4 and KQ5 reported on harms. Rates of reported adverse events were similar among groups randomized to valacyclovir and placebo, including dizziness, headache, and nausea (eTable 11 in the Supplement).

### Discussion

This review did not identify any eligible studies directly assessing the benefits or harms of serologic screening for HSV-2 compared with no screening. Therefore, the literature that might establish an indirect chain of evidence from multiple questions that link screening to health outcomes (KQ2 through KQ7) was reviewed. Table 4 provides a summary of findings in this evidence review. Estimates for specificity varied and were imprecise, without a clear explanation for the observed heterogeneity. Potential explanations for false-positive serologic test results include cross-reactivity with HSV-1 (or other viruses), recent seroconversion, geographic variability in HSV-2 strain variants, and laboratory error. At higher cutoffs, estimates of sensitivity and specificity from 8 studies in Africa were still imprecise. There was evidence from 2 uncontrolled observational studies that detection of unexpected HSV-2 by screening is associated with potential psychosocial harms, including anxiety, worry, and distress. Other potential harms of serologic screening include false-positive results that lead to psychosocial distress and costs of confirmatory testing.

The estimates of the accuracy of serologic tests are generally applicable to populations with a higher prevalence of HSV-2 infection than general primary care populations in the United States. The majority of studies assessing the accuracy of HerpeSelect enrolled a population with HSV-2 prevalence greater than 40% based on Western blot. Use of HerpeSelect in a population with lower prevalence, similar to that of US adults, would greatly increase the number of false-positive test results. For example, in a hypothetical population of 100 000 persons with a prevalence of asymptomatic HSV-2 of 50% (similar to the prevalence in included studies), with test sensitivity of 99% and specificity of 81%, there would be an estimated 49 500 true-positive results and 9500 false-positive results (positive predictive value, 84%). If the prevalence instead were 16% (similar to the seroprevalence in the general US adult population among people with unknown symptom status), the number of true-positive results would be estimated at 15 840, and the number of false-positive results would be estimated at 15 960 (positive predictive value, 50%). True-positive results would decrease further, and false-positive results would increase further if the prevalence were less than 16%.

If sensitivity was unchanged, screening a lower-prevalence population would reduce the number of false-negative test results, although the negative predictive value would change little. It is possible, however, that the sensitivity of the screening tests could be lower in a lower-prevalence population, owing to such factors as lower antibody levels, thus increasing the number of false-negative results per 1000 persons tested. The direction of these changes with prevalence would be similar regardless of which cutpoints were used.

There was limited evidence evaluating preventive interventions for asymptomatic adults who screen positive for HSV-2. No studies enrolled pregnant women or adolescents, and none assessed behavioral counseling interventions. Two RCTs (total of 129 participants) assessed the benefit of preventive antiviral medications for reducing HSV-2 viral shedding and symptomatic occurrences among adults seropositive for HSV-2 who reported no prior genital herpes symptoms. Evidence from these 2 trials does not allow an accurate estimate of the benefit of preventive antiviral medications for improving health outcomes. The 2 trials differed in several ways. They assessed different medications (valacyclovir and acyclovir), recruited from different sources, and used different tests to establish HSV-2 infection. Both assessed outcomes over a short time (6-8 weeks) and relied on self-report to ascertain symptom occurrence. This duration is likely inadequate to evaluate whether antiviral medications reduce symptom incidence among populations who have been asymptomatic. Results were inconsistent and imprecise; 1 trial found benefit for valacyclovir compared with placebo for reducing viral shedding and symptom occurrences, and the other found no statistically significant differences between groups.

Similarly, the 2 RCTs assessing preventive antiviral medications for reducing HSV-2 transmission between serodiscordant partners were heterogeneous and found inconsistent results. One enrolled immunocompetent couples from primarily industrialized countries, while the other enrolled couples discordant for both human immunodeficiency virus and HSV-2 from sub-Saharan Africa.
### Table 4. Summary of Evidence: Serologic Screening for Genital Herpes*

<table>
<thead>
<tr>
<th>Key Question Topic</th>
<th>No. of Studies</th>
<th>No. of Participants</th>
<th>Study Design</th>
<th>Summary of Findings (Including Consistency and Precision)</th>
<th>Applicability</th>
<th>Limitations (Including Reporting Bias)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key question 1: Benefits of screening</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>No studies were identified that directly evaluated the benefits of screening compared with no screening.</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Key question 2: Accuracy of serologic screening tests</td>
<td>11</td>
<td>Total: 7129; pooled analyses: 6537 (HerpeSelect, 1.1 cutpoint); 5516 (HerpeSelect, 2.2-2.5 cutpoint); 1512 (biokit HSV-2)</td>
<td>Cross-sectional</td>
<td>Pooled sensitivity for detecting HSV-2 with HerpeSelect (1.1 cutpoint) was 99% (95% CI, 97%-100%) and slightly lower (95%) at higher cutpoints. Pooled specificity of biokit HSV-2 was 84% (95% CI, 73%-91%). Pooled specificity for detecting HSV-2 with HerpeSelect (at manufacturer’s cutpoint) was 81% (95% CI, 68%-90%) and slightly higher (89%) at higher cutpoints. Pooled specificity of biokit HSV-2 was 95% (95% CI, 93%-97%). Overall, findings were consistent but imprecise.</td>
<td>Populations from African countries that have a high prevalence of HSV-2 infection (&gt;50%)</td>
<td>Evidence identified for only 2 FDA-approved HSV-2 serologic tests; most studies excluded equivocal test results from calculations of test accuracy (or did not describe the handling of missing data).</td>
</tr>
<tr>
<td>Key question 3: Harms of screening</td>
<td>0</td>
<td>57</td>
<td>Qualitative study; cohort study</td>
<td>The qualitative study found that participants with a new HSV-2 diagnosis had short-term emotional responses (eg, distress, sadness), short-term psychological responses (eg, fear of telling sex partners), and perceived ongoing responses (eg, feeling sexually undesirable). The cohort study found that individual items frequently reported as interfering in daily life on the herpes HRQOLQ included “It is difficult to forget I have herpes” (63%); “I worry about giving herpes to someone” (56%); “I worry about people finding out I have herpes” (48%); and others. Findings were consistent but imprecise.</td>
<td>Asymptomatic persons with no known history of genital herpes</td>
<td>Studies are uncontrolled; due to study design and outcome measures, estimating magnitude of effect or assessing precision is not possible.</td>
</tr>
<tr>
<td>Key question 4: Benefits of treatment: shedding</td>
<td>2</td>
<td>129</td>
<td>Crossover RCTs</td>
<td>The valacyclovir trial found that those taking valacyclovir (1 g daily) had fewer subclinical days with any genital HSV-2 viral shedding detected over 6-8 wk than those taking placebo (1.5% vs 5.1%, respectively, P &lt; .001). The famciclovir trial found that those taking famciclovir (250 mg twice daily) had fewer subclinical days with any genital HSV-2 viral shedding detected over 6-8 wk than placebo (5.7% vs 5.0%, respectively; RR, 0.8 [95% CI, 0.41-1.56]; P = .52). Findings were inconsistent and imprecise.</td>
<td>Asymptomatic adults with HSV-2 infection diagnosed (or confirmed) by Western blot</td>
<td>Studies assessed different medications over a short duration; sample sizes were small, and overall attrition was &gt;20% in both trials.</td>
</tr>
<tr>
<td>Key question 5: Benefits of treatment for asymptomatic adults</td>
<td>2</td>
<td>129</td>
<td>Crossover RCTs</td>
<td>The valacyclovir trial found that those taking valacyclovir (1 g daily) had lower incidence of subclinical shedding of genital herpes symptoms at 6-8 wk than placebo (12% vs 23%, respectively; P = .033). The famciclovir trial found that those taking famciclovir (250 mg twice daily) had lower incidence of self-reported genital herpes symptoms at 6-8 wk than those taking placebo (17.5% vs 17.2%, respectively; P value NR). Findings were inconsistent and imprecise.</td>
<td>Asymptomatic adults with HSV-2 infection diagnosed (or confirmed) by Western blot</td>
<td>Incidence was self-reported; outcomes were measured over a relatively short duration; sample sizes were small, and overall attrition was &gt;20% in both trials.</td>
</tr>
<tr>
<td>Key question 5: Benefits of treatment for serodiscordant couples</td>
<td>2</td>
<td>2421</td>
<td>RCTs</td>
<td>The valacyclovir trial found that participants whose partners took valacyclovir (1 g daily) had lower incidence of HSV-2 seroconversion at 32 wk than those whose partners took placebo (HR, 0.52 [95% CI, 0.27-0.99]; P = .04). The acyclovir trial found that participants whose partners took acyclovir had no difference in incidence of HSV-2 seroconversion at 78 wk compared with those whose partners took placebo (HR, 1.35 [95% CI, 0.83-2.20]; P = .220). Findings were inconsistent and imprecise.</td>
<td>Asymptomatic adults with known, ongoing exposure to genital herpes from a partner</td>
<td>Studies assessed different medications over different durations in populations that were heterogeneous.</td>
</tr>
<tr>
<td>Key question 6: Harms of treatment</td>
<td>1</td>
<td>62</td>
<td>RCT</td>
<td>Incidence of self-reported adverse events were similar between groups (headache, nausea). Findings were imprecise, consistency NA</td>
<td>Generally healthy asymptomatic nonpregnant adults</td>
<td>Unclear if adverse events were prespecified.</td>
</tr>
</tbody>
</table>

Abbreviations: FDA, US Food and Drug Administration; HR, hazard ratio; HRQOLQ, Health-Related Quality of Life Questionnaire; HSV, herpes simplex virus; NA, not applicable; NR, not reported; RCT, randomized clinical trial; RR, relative risk.

*Quality of evidence was fair for all studies in this table.
The trials assessed different medications (valacyclovir and acyclovir) and over different durations (8 months and a median of 18 months). One trial found benefit for valacyclovir compared with placebo for reducing symptomatic HSV-2 infection and HSV-2 seroconversion in the susceptible partner; however, the magnitude of benefit for symptomatic reduction was modest, and results were imprecise (0.5% vs 2.2%, respectively; hazard ratio, 0.25 [95% CI, 0.08-0.75]).

One trial assessed harms of medications; adverse events were similar between groups randomized to valacyclovir and placebo. Other review studies have concluded that there are few harms in nonpregnant adults. It is unclear whether these results would apply to people who have less frequent recurrences (or who are asymptomatic).

Conclusions
Serologic screening for genital herpes is associated with a high rate of false-positive test results and potential psychosocial harms. Evidence from RCTs does not establish whether preventive antiviral medication for asymptomatic HSV-2 infection has benefit.
Evidence Report: Serologic Screening for Genital Herpes


